NASDAQ:ARRYArray Biopharma Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Array Biopharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Compare Share Today's Range N/A50-Day Range$47.85MA: $47.85▼$47.8552-Week Range N/AVolume206,508 shsAverage Volume4.99 million shsMarket Capitalization$10.68 billionP/E RatioN/ADividend YieldN/ABeta1.7 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer and other diseases in North America, Europe, and the Asia Pacific. It provides BRAFTOVITM (encorafenib) capsules in combination with MEKTOVI (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAF mutation. The company's lead clinical programs include encorafenib and binimetinib that are investigated in approximately 30 clinical trials for various solid tumor indications, including a Phase III trial in BRAF-mutant colorectal cancer. Its product pipeline also includes ipatasertib, an AKT inhibitor that is in Phase III trial to treat prostate or breast cancers; selumetinib, a MEK inhibitor for cancer; larotrectinib, a PanTrk inhibitor that is in a Phase II/registration clinical trial for cancer; tucatinib, a HER2 inhibitor for breast cancer, which is in Phase II/registration trial; and ARRY-797 that is in Phase III clinical trial for Lamin A/C-related dilated cardiomyopathy. In addition, the company is developing varlitinib/ASLAN001, a Pan-HER2 inhibitor for gastric cancer; ARRY-382, a CSF1R inhibitor that is in Phase II clinical trial to treat cancer; motolimod/VTX-2337, a Toll-like receptor that is in Phase II clinical trial for cancer; and prexasertib/LY2606368, a CHK-1 inhibitor, which is in multiple Phase I or II clinical trials for cancer. Further, its drug candidates in Phase I clinical trials include GDC-0575, a CHK-1 inhibitor for cancer; LOXO-292, a RET inhibitor to treat cancer; and LOXO-195, a Trk inhibitor for cancer. Additionally, its drug candidates include Ganovo/danoprevir, a protease inhibitor for hepatitis C virus. The company was founded in 1998 and is headquartered in Boulder, Colorado.Read More Beat the Market (BTM) Rank™ 3.1 Analyst's Opinion Consensus RatingArray Biopharma has received a consensus rating of Hold. The company's average rating score is 2.11, and is based on 1 buy rating, 8 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $39.14, Array Biopharma has a potential upside of ∞ from its current price of $0.00.Amount of Analyst CoverageArray Biopharma has received no research coverage in the past 90 days. Previous Next 3.0 Community Rank Outperform VotesArray Biopharma has received 508 “outperform” votes. (Add your “outperform” vote.)Underperform VotesArray Biopharma has received 329 “underperform” votes. (Add your “underperform” vote.)Community SentimentArray Biopharma has received 60.69% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Array Biopharma and other stocks. Vote “Outperform” if you believe ARRY will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ARRY will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldArray Biopharma does not currently pay a dividend.Dividend GrowthArray Biopharma does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Array Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.10% of the stock of Array Biopharma is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Array Biopharma are expected to decrease by -29.41% in the coming year, from ($0.51) to ($0.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Array Biopharma is -65.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Array Biopharma is -65.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 3.1Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.21 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:ARRY Previous Symbol CUSIP04269X10 CIK1100412 Webhttp://www.arraybiopharma.com/ Phone303-381-6600Debt Debt-to-Equity Ratio0.45 Current Ratio5.70 Quick Ratio5.65Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$173.77 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$1.04 per share Price / BookN/AProfitability EPS (Most Recent Fiscal Year)($0.73) Net Income$-147,340,000.00 Net Margins-52.64% Return on Equity-48.51% Return on Assets-24.15%Miscellaneous Employees298 Outstanding Shares223,130,000Market Cap$10.68 billion Next Earnings DateN/A OptionableOptionable Receive ARRY News and Ratings via Email Sign-up to receive the latest news and ratings for ARRY and its competitors with MarketBeat's FREE daily newsletter. Array Biopharma (NASDAQ:ARRY) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of Array Biopharma? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Array Biopharma in the last year. There are currently 8 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Array Biopharma. How were Array Biopharma's earnings last quarter? Array Biopharma Inc (NASDAQ:ARRY) released its earnings results on Tuesday, October, 30th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.10. The biopharmaceutical company had revenue of $56.91 million for the quarter, compared to analyst estimates of $34.47 million. Array Biopharma had a negative return on equity of 48.51% and a negative net margin of 52.64%. Array Biopharma's revenue was up 91.3% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.22) earnings per share. View Array Biopharma's earnings history. What price target have analysts set for ARRY? 9 analysts have issued 1-year price targets for Array Biopharma's shares. Their forecasts range from $25.00 to $48.00. On average, they anticipate Array Biopharma's share price to reach $39.14 in the next year. View analysts' price targets for Array Biopharma. Has Array Biopharma been receiving favorable news coverage? News stories about ARRY stock have trended very negative recently, according to InfoTrie. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Array Biopharma earned a news impact score of -3.3 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutArray Biopharma. Who are some of Array Biopharma's key competitors? Some companies that are related to Array Biopharma include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), Neurocrine Biosciences (NBIX), EXACT Sciences (EXAS), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). What other stocks do shareholders of Array Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Array Biopharma investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Medivation (MDVN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX), United Continental (UAL), Exelixis (EXEL), Kite Pharma (KITE) and Omeros (OMER). Who are Array Biopharma's key executives? Array Biopharma's management team includes the following people: Mr. Ron Squarer, CEO & Director (Age 52)Mr. Jason Haddock, Chief Financial Officer (Age 49)Mr. Andrew R. Robbins, Chief Operating Officer (Age 43)Dr. Victor Sandor, Chief Medical Officer (Age 53)Dr. Nicholas A. Saccomano, Chief Scientific Officer (Age 60) What is Array Biopharma's stock symbol? Array Biopharma trades on the NASDAQ under the ticker symbol "ARRY." How big of a company is Array Biopharma? Array Biopharma has a market capitalization of $0.00 and generates $173.77 million in revenue each year. The biopharmaceutical company earns $-147,340,000.00 in net income (profit) each year or ($0.73) on an earnings per share basis. Array Biopharma employs 298 workers across the globe. View additional information about Array Biopharma. What is Array Biopharma's official website? The official website for Array Biopharma is http://www.arraybiopharma.com/. How can I contact Array Biopharma? Array Biopharma's mailing address is 3200 Walnut Street, Boulder CO, 80301. The biopharmaceutical company can be reached via phone at 303-381-6600 or via email at [email protected] This page was last updated on 4/9/2020 by MarketBeat.com StaffFeatured Article: What is Compound Annual Growth Rate (CAGR)?